Tirzepatide
A once-weekly dual GIP/GLP-1 receptor agonist that produced the largest mean weight loss of any FDA-approved anti-obesity medication and beat semaglutide head-to-head.
Tirzepatide is a 39-amino-acid synthetic peptide and the first FDA-approved dual agonist of the GIP and GLP-1 incretin receptors, marketed by Eli Lilly as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). By activating two complementary metabolic pathways with a single molecule, it produces greater appetite suppression, glycemic control, and weight reduction than selective GLP-1 agonists. In the phase 3 SURMOUNT-1 trial it achieved a mean 22.5% body weight reduction over 72 weeks, and it outperformed semaglutide in direct head-to-head comparisons.
Class
Synthetic 39-amino-acid dual GIP/GLP-1 receptor agonist peptide
Half-life
~5 days (~120 hours), enabled by a C20 fatty diacid albumin-binding modification
Routes
Subcutaneous
Category
Weight Loss & Metabolic
Researched benefits
What it's studied for
Substantial weight reduction
In the phase 3 SURMOUNT-1 trial, tirzepatide 15 mg produced a mean body weight reduction of 22.5% over 72 weeks (vs 2.4% for placebo), the highest of any anti-obesity medication at the time, with 36.2% of participants losing 25% or more of body weight — a magnitude historically seen only with bariatric surgery.
Superior efficacy versus semaglutide
In the head-to-head SURMOUNT-5 trial (2024), tirzepatide 10 mg and 15 mg produced significantly greater weight loss than semaglutide 2.4 mg (20.2% vs 13.7% at 72 weeks), and SURPASS-2 showed greater HbA1c reduction versus semaglutide 1 mg in type 2 diabetes.
Glycemic control in type 2 diabetes
Across the SURPASS program, tirzepatide reduced HbA1c by up to roughly 2.4 percentage points, delivering best-in-class glycemic control without increasing serious hypoglycemia risk when used without insulin or sulfonylureas.
Improved cardiometabolic markers
Trials reported improvements in lipid profiles (triglycerides, LDL, HDL), reductions in waist circumference and visceral adiposity, and lower blood pressure, extending the drug's benefit beyond the scale.
Potential lean-mass sparing via GIP
The GIP receptor component is proposed to improve adipose lipid metabolism and may reduce the loss of lean body mass that accompanies caloric restriction, though dedicated body composition studies are still needed to confirm this advantage over GLP-1-only agents.
Cardiovascular and heart-failure outcomes
SURPASS-CVOT (NEJM 2025) met non-inferiority for major adverse cardiovascular events versus dulaglutide and favored tirzepatide on expanded MACE (HR 0.88), and the SUMMIT trial in HFpEF plus obesity showed HR 0.62 for cardiovascular death or worsening heart failure.
Mechanism
How it works
Tirzepatide activates two incretin receptors simultaneously with a single 39-amino-acid molecule: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GLP-1 activation suppresses appetite through central pathways, slows gastric emptying, and potentiates glucose-dependent insulin secretion while reducing glucagon. GIP activation independently stimulates insulin release and modulates adipose tissue metabolism, adding a complementary mechanism that operates outside the GLP-1 pathway.
The dual mechanism produces greater appetite suppression and metabolic improvement than either receptor pathway alone, which accounts for the superior weight reduction seen versus selective GLP-1 agonists such as semaglutide. GIP signaling in adipose tissue is proposed to improve lipid metabolism and may help protect lean body mass during weight loss, and some evidence suggests the GIP component can blunt certain GLP-1-associated gastrointestinal effects.
Structurally, the peptide is based on the native GIP sequence with modifications that confer activity at both receptors, and it carries a C20 fatty diacid side chain attached via a linker. This fatty-acid modification promotes reversible binding to serum albumin, extending the plasma half-life to approximately 5 days and enabling convenient once-weekly subcutaneous dosing.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
The prescription product is supplied ready-to-use as a KwikPen auto-injector or single-dose vial/pen. Compounded or research-grade tirzepatide is supplied either ready-to-inject or as a lyophilized powder requiring reconstitution with bacteriostatic water per the vendor protocol. Reconstituted material keeps roughly four to eight weeks refrigerated; match vial size to weekly dose so it is used within that window.
Beginner
- Dose
- 2.5 mg (2500 mcg)
- Frequency
- Once weekly
- Timing
- Same day each week
- Duration
- 4 weeks
- Route
- Subcutaneous
Starting/tolerance dose, not a therapeutic dose; establishes GI tolerability before escalation.
Intermediate
- Dose
- 5 mg to 10 mg (titrated)
- Frequency
- Once weekly
- Timing
- Same day each week
- Duration
- Escalate every 4 weeks (5 mg, 7.5 mg, 10 mg)
- Route
- Subcutaneous
Step up by 2.5 mg every 4 weeks as tolerated; most users settle at the lowest dose that keeps working.
Advanced
- Dose
- 12.5 mg to 15 mg (maximum)
- Frequency
- Once weekly
- Timing
- Same day each week
- Duration
- Ongoing maintenance after ~20-week escalation
- Route
- Subcutaneous
Full titration to the 15 mg maximum over roughly 20 weeks; maintain at highest tolerated dose.
- Titration schedule per FDA labeling: weeks 1-4 at 2.5 mg, weeks 5-8 at 5 mg, weeks 9-12 at 7.5 mg, weeks 13-16 at 10 mg, weeks 17-20 at 12.5 mg, week 21+ at 15 mg.
- Dosing is fixed-escalation, not weight-based. Slow, stepwise escalation is essential to limit gastrointestinal side effects.
- This is a chronic metabolic therapy by design, not a short course; SURMOUNT-4 showed weight tends to return after discontinuation, so long-term maintenance planning matters.
- Studied doses in SURMOUNT and SURPASS ranged from 2.5 mg through 15 mg weekly under clinical supervision with mandatory titration.
Evidence
Research & clinical studies (8)
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Over 72 weeks, tirzepatide 15 mg reduced mean body weight by roughly 21-22.5% versus about 3% for placebo in adults with obesity, with a large share of participants achieving 20-25% or greater weight loss.
PMID 35658024Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide 15 mg reduced mean body weight by 14.7% over 72 weeks versus 3.2% for placebo in adults with obesity and type 2 diabetes, with more than 79% of participants achieving at least 5% weight reduction.
PMID 37385275Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Over 40 weeks tirzepatide at all three doses produced significantly greater HbA1c and body weight reductions than semaglutide 1 mg, with the highest dose achieving about 5.5 kg additional weight loss over semaglutide.
PMID 34170647Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study
In real-world practice tirzepatide produced meaningful reductions in HbA1c and body weight over 24 weeks, with baseline glycemia rather than BMI being the primary predictor of response.
PMID 42217105Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus
Tirzepatide produced significant reductions in HbA1c and body weight while improving lipid parameters and lowering blood pressure, without increasing serious hypoglycemia and with primarily mild GI adverse events.
PMID 42211143The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms
GLP-1 receptor agonists including tirzepatide are associated with hair-loss conditions such as telogen effluvium, with risk potentially increasing with longer treatment, greater weight loss, and higher doses, though the evidence remains conflicting.
PMID 42210891Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies
Translational evidence suggests GLP-1 receptor agonists including tirzepatide may influence inflammatory and fibrotic pathways relevant to lipedema, but direct patient evidence is very limited and further research is needed.
PMID 42210892DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model
A DNA-based intramuscular delivery platform enabled incretin receptor agonists to produce sustained weight loss and glucose control lasting over a year from a single administration in an obesity model.
PMID 42211692Combinations
Stacking & blends
AOD-9604 + Tirzepatide: Advanced Body Composition
Fat reduction and improved body composition
AOD-9604, a C-terminal fragment of human growth hormone associated with selective lipolytic activity, is paired with tirzepatide's dual GIP/GLP-1 appetite regulation and energy balance to address fat reduction through complementary peripheral and central mechanisms.
Tirzepatide + Cagrilintide
Amplified appetite suppression and weight loss
Adding the long-acting amylin analog cagrilintide to tirzepatide's dual-incretin mechanism is explored as a synergistic combination for enhanced satiety and metabolic effect.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Severe gastrointestinal disease
- Pregnancy or breastfeeding
- Caution with insulin or sulfonylureas due to hypoglycemia risk
Gastrointestinal effects dominate and are concentrated in the dose-escalation phase, generally mild-to-moderate and diminishing over time. Serious but rare risks include pancreatitis, gallbladder disorders (cholelithiasis with rapid weight loss), and acute kidney injury from dehydration. Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent findings. Discontinuation rates due to adverse events ranged from about 4.3% to 7.1% across doses in SURMOUNT-1. FDA prescribing protocols monitor HbA1c and fasting glucose, calcitonin for thyroid C-cell risk, lipase for pancreatitis, and baseline renal and hepatic panels.
FAQ
Tirzepatide — common questions
What is tirzepatide?
Tirzepatide is a once-weekly injectable dual agonist of the GLP-1 and GIP receptors, FDA-approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It is the first dual-incretin drug, combining two complementary metabolic pathways in a single 39-amino-acid molecule.
How is tirzepatide dosed?
It is a once-weekly subcutaneous injection. Everyone starts at 2.5 mg for the first four weeks (a tolerance dose), then steps up to 5 mg and can climb by 2.5 mg every four weeks up to a 15 mg maximum. Most people settle at the lowest dose that keeps working, and it is injected on the same day each week.
How does tirzepatide compare to semaglutide?
Tirzepatide hits two receptors (GIP and GLP-1) while semaglutide hits one (GLP-1). In head-to-head trials tirzepatide produced greater weight loss (20.2% vs 13.7% in SURMOUNT-5) and larger HbA1c drops. Semaglutide has a larger body of long-term safety data; tirzepatide has superior head-to-head efficacy data.
What are the side effects of tirzepatide?
The most common are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite, typically mild-to-moderate and concentrated during dose escalation. Serious but rare risks include pancreatitis and gallbladder problems, and there is a boxed warning for thyroid C-cell tumors based on rodent studies.
Is tirzepatide FDA approved?
Yes. It was approved as Mounjaro in May 2022 for type 2 diabetes and as Zepbound in November 2023 for chronic weight management. Research-grade tirzepatide sold by third-party labs is a separate supply chain intended for laboratory use only and is not the FDA-approved prescription product.
What happens when you stop tirzepatide?
As with other GLP-1-based therapies, weight tends to return after discontinuation, as shown in SURMOUNT-4. It is designed as a chronic metabolic therapy rather than a short course, so long-term maintenance planning is important from the start.
Does tirzepatide cause muscle loss?
Some lean mass is lost along with fat during weight reduction — DEXA data suggest roughly 25-30% of total loss can be lean mass without resistance training, similar to semaglutide. The GIP component may help spare lean mass, but preserving muscle still requires intentional strength training and adequate protein intake.
Can I get tirzepatide from a compounding pharmacy?
Compounding access depends on FDA shortage status and 503A/503B regulations, both of which shifted during 2024-2025. When tirzepatide is on the FDA shortage list, 503A pharmacies may compound it; the FDA ended the shortage designation in late 2024, after which most compounding is prohibited.
